India on Wednesday banned exports of anti-malarial drug hydroxychloroquine which is believed to have some positive effect on treatment of the coronavirus (COVID-19)
India on Wednesday banned exports of anti-malarial drug hydroxychloroquine which is believed to have some positive effect on treatment of the coronavirus (COVID-19)|Representational image
CORONAVIRUS UPDATES

COVID-19: India bans export of hydroxychloroquine to meet demand

India imposes ban on export of anti-malarial drug hydroxychloroquine which is believed to have some positive effect on treatment of coronavirus aka COVID-19

Team EastMojo

Team EastMojo

New Delhi: The government of India, in a significant development, has decided to prohibit the export of hydroxychloroquine with immediate effect. Hydroxychloroquine is considered as an effective drug against COVID-19 — and its associated formulations. This was disclosed in a notification issued on Wednesday.

Because of its increasing demands in the domestic market, the Centra has taken the decision keeping the greater interest of the citizens of the country in mind. This drug has been disappearing fast from shelves in chemist shops across the country because of a recent surge in both domestic and global demand although enough tests have not been done to prove that it works against the virus conclusively.

“Export of hydrochloroquine and formulations made from it, however, shall be allowed under specific conditions,” according to the notification issued by the Directorate General of Foreign Trade.

The notification stated: Hydroxychloroquine and formulations can be exported from units in Special Economic Zones and Export Oriented Units. Exports will also be permitted in cases where they are made to meet export obligations or have been recommended under humanitarian grounds on case to case basis by the Ministry of External Affairs.

So far, the export of hydroxychloroquine and formulations was free in India, but due to a sudden spike in demand in the world and domestic market and the resultant shortage in the country, a decision to impose export prohibition was taken. The Indian Council for Medical Research has recommended hydroxychloroquine for high-risk population such as asymptomatic healthcare workers involved in the care of suspected or confirmed cases of COVID-19 and asymptomatic household contacts of laboratory-confirmed cases.

While enough clinical testing to prove the efficacy of hydroxychloroquine (which is usually used to treat malaria, lupus and rheumatoid arthritis) in the fight against COVID-19 has not taken place, data from countries such as China suggest that it may be useful against the virus.

US President Donald Trump also endorsed it by recently tweeting that the combination of hydroxychloroquine with another antibiotic azithromycin could be a game-changer in the history of medicine. However, this was frowned upon by many medical practitioners.

For more such stories, follow us on Facebook, Twitter and Instagram. Activate Website Notifications to stay updated.

EastMojo
www.eastmojo.com